Can You Switch from Humira to Skyrizi If Symptoms Aren't Improving?
Yes, switching from Humira (adalimumab) to Skyrizi (risankizumab) is possible and common for patients with plaque psoriasis, psoriatic arthritis, or Crohn's disease when Humira fails to control symptoms. Both are biologics that target inflammation, but Skyrizi inhibits IL-23 while Humira blocks TNF-alpha, offering a different mechanism that can work when TNF inhibitors lose effectiveness.[1][2] Gastroenterologists and dermatologists often recommend this after confirming inadequate response via clinical assessment, such as PASI scores for psoriasis or CDAI for Crohn's.
How Does the Switching Process Work?
Your doctor reviews your disease activity, infection history, and lab results (like TB screening) before starting Skyrizi. No washout period is typically needed—Skyrizi can begin right after your last Humira dose, as their half-lives don't overlap in a way that causes issues.[3] Skyrizi dosing starts with IV infusions for Crohn's (600 mg at weeks 0, 4, 8), then subcutaneous maintenance, or subQ only for psoriasis (150 mg at weeks 0, 4, then every 12 weeks).[2] Expect monitoring for 1-2 weeks post-switch for immune response.
What Improvement Timeline to Expect on Skyrizi?
Skyrizi often shows faster skin clearance in psoriasis (70-80% PASI 90 response by week 16) compared to Humira's 40-50%, per head-to-head trials like IMMVent.[4] For Crohn's, 40% achieve clinical remission by week 24 versus Humira's lower rates in refractory cases. Full benefits may take 12-24 weeks; if no improvement by then, further switches (e.g., to ustekinumab) are options.
Common Risks and Side Effects During Switch
Infection risk persists across both drugs (upper respiratory or herpes reactivation), but Skyrizi has a lower rate of serious infections (3-5% vs. Humira's 8-10%).[1][5] Watch for injection-site reactions on Skyrizi (10-15% of patients) or paradoxical worsening of symptoms early on. No increased malignancy risk beyond Humira in trials up to 5 years.[2] Avoid live vaccines.
Who Makes Skyrizi and Cost Considerations?
AbbVie manufactures Skyrizi, the same company behind Humira, which faces patent challenges allowing biosimilars but keeps Skyrizi protected until at least 2033.[6] List price is $18,000-$20,000 per year, often covered by insurance with prior authorization showing Humira failure. Patient assistance programs like myAbbVie Assist reduce copays to $5/month for eligible uninsured patients.[7]
When Might Switching Not Be Recommended?
Skip if you have active infections, recent live vaccines, or heart failure history (Humira carries a stronger warning). For ulcerative colitis, Skyrizi lacks approval—stick to approved options like Entyvio. Always consult your specialist; self-switching risks flares or complications.[1]
Sources:
[1] Skyrizi.com prescribing information
[2] RxList Skyrizi overview
[3] Switching biologics in IBD (PMC)
[4] IMMvent trial (NEJM)
[5] FDA Skyrizi safety data
[6] DrugPatentWatch.com Skyrizi patents
[7] AbbVie patient assistance